Mepivacaine Hydrochloride Accord Healthcare (Mepivacaine Hydrochloride)

The drug reversibly blocks voltage‑gated sodium channels on neuronal membranes, stabilising them in an inactive state. This prevents sodium influx, halting depolarisation and stopping the propagation of nerve impulses, which results in a temporary loss of sensation.

The appropriate dose of Mepivacaine Hydrochloride is determined by the prescribing clinician based on the type of procedure, patient weight, age, and overall health. Dosage guidelines are provided in the product labeling and must be followed by the healthcare professional.

Safety data for Mepivacaine Hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against risks and consider alternative agents when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Mepivacaine is an amide‑type local anesthetic with a rapid onset and intermediate duration, similar to lidocaine but with slightly longer analgesic effect and less vasodilatory activity. Compared with bupivacaine, it has a faster onset and lower cardiotoxic potential, making it suitable for shorter procedures.

The injectable solution should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration.

Mepivacaine Hydrochloride is administered by injection via epidural, infiltration, or perineural routes. The clinician selects the appropriate technique, prepares the injection site aseptically, and injects the calculated volume slowly while monitoring the patient for any adverse reactions.

Serious risks include allergic reactions such as anaphylaxis, cardiovascular toxicity (hypotension, arrhythmias, cardiac arrest), central nervous system toxicity (seizures, loss of consciousness), and methemoglobinemia. Prompt recognition and supportive management are essential if these events occur.

Patients with known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or significant hepatic impairment should avoid Mepivacaine Hydrochloride. Clinicians must assess each patient individually before administration.